Skip to main content

Super navigation

  • Now approved in the US: VYVGART
  • Newsroom
    • The Latest
    • Press releases
    • argenx Stories
    • Downloadable assets
A
A

Main navigation additional

  • Home
  • Contact us
  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient Access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & presentations
    • Financial Reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx Stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Ethics and Responsibility
    • Contact us
Home

Secondary navigation additional

  • Contact

Secondary/mobile navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient Access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & presentations
    • Financial Reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx Stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Ethics and Responsibility
    • Contact us

Breadcrumb

  1. Home
  2. Press Releases

Press Releases

  • Any
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • (-) 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
Reset

2015

December 3, 2015
argenx to host workshop and webcast announcing topline clinical TCL data and preclinical AML data from ARGX-110 program
November 16, 2015
argenx reports third quarter 2015 financial results and provides business update
October 29, 2015
argenx to Present at Key Investor Conferences
October 21, 2015
arGEN-X Completes First Dosing of ARGX-113 for Severe Autoimmune Disorders
February 22, 2015
arGEN-X’ Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6
August 24, 2015
arGEN-X Announces Half-Year Results For 2015
August 18, 2015
arGEN-X to Host Conference Call & Webcast to Report Half-Year Results on 26 August 2015
August 6, 2015
arGEN-X to Present at Wedbush PacGrow Healthcare Conference
July 29, 2015
arGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers
July 14, 2015
Change to the Board of Directors
June 17, 2015
Preliminary Phase I results of ARGX-110 in patients with T-cell lymphomas presented at ICML
May 31, 2015
arGEN-X to Present at Jefferies 2015 Global Healthcare Conference on Tuesday, 2 June at 8:00am EDT

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Next page Next ›
  • Last page Last »
TwitterFacebookLinkedInWhatsApp
Home
  • Home
  • Contact us

Footer navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient Access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & presentations
    • Financial Reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx Stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Ethics and Responsibility
    • Contact us
2022 © argenx
Disclaimer
Privacy policy
Regulations